助手标题  
全文文献 工具书 数字 学术定义 翻译助手 学术趋势 更多
查询帮助
意见反馈
   relative bioequivalence 的翻译结果: 查询用时:0.071秒
图标索引 在分类学科中查询
所有学科
药学
更多类别查询

图标索引 历史查询
 

relative bioequivalence
相关语句
  相对生物利用度
     The relative bioequivalence of rifampicin,isoniazid and pyrazi-namide of the tested preparation were(99.88±12.92)%,(103.84±24.10)%and(102.57±12.31)%respectively.
     受试制剂中利福平、异烟肼和吡嗪酰胺的相对生物利用度分别为(99. 88±12. 92) %、(103 .84±24. 10) %、(102. 57±12. 31) %。
短句来源
     The relative bioequivalence was:(95.3±7.3)% for amoxicillin;
     阿莫西林的相对生物利用度为 (95 .3±7.3) % ;
短句来源
     The relative bioequivalence of the test preparation was(97±12)%.
     t_(1\2β)分别为(1.9±2.3)h和(1.9±1.5)h,2种制剂的主要药动学参数无显著差异(P>0.05),受试制剂的相对生物利用度为(97±12)%。
短句来源
     The relative bioequivalence of the TT was 107.04 + 28.90% compared to RT.
     试验片的相对生物利用度F=107.04%±28.90%。
短句来源
     CONCLUSION:The relative bioequivalence of polyferose capsules is101.02%which indicates that polyferose capsule is a bioequivalent product of Niferex capsule.
     结论 :多糖铁胶囊的相对生物利用度为101 02 % ,与力蜚能胶囊为生物等效制剂
短句来源
更多       
  “relative bioequivalence”译为未确定词的双语例句
     The relative bioequivalence of adefovir dipivoxil was 97.6%.
     新晶型阿德福韦酯相对于晶型Ⅰ阿德福韦酯的生物利用度为97.6%。
短句来源
     Clinical pharmacokinetics and relative bioequivalence of domestic cephradine cap sule
     国产头孢拉定临床药代动力学及其胶囊剂的生物等效性
短句来源
     The Pharmacokinetics and Relative Bioequivalence of Nefopam Hydrochloride Sustain-released Tablet in Healthy Volunteers
     盐酸奈福泮缓释片健康人体药代动力学及生物等效性实验
短句来源
     Pharmacokinetics and Relative Bioequivalence of Single and Multiple Oral Doses of Ibuprofen Sustained-Release Capsules
     单剂量及多剂量口服布洛芬缓释胶囊的药物动力学与生物等效性研究
短句来源
     OBJECTIVE:To study the pharmacokinetics and relative bioequivalence of domestic and imported indinavir sulfate capsules.
     目的研究国产与进口硫酸茚地那韦胶囊的生物等效性。
短句来源
更多       
  相似匹配句对
     Relative bioavailability and bioequivalence of glipizide capsules
     格列吡嗪胶囊剂的相对生物利用度和生物等效性评价
短句来源
     Assessment on Relative Bioavailability and Bioequivalence of Glipizide
     格列吡嗪胶囊的相对生物利用度及其生物等效性评价
短句来源
     Being relative to O.
     相对于O.
短句来源
     On Relative Topology
     关于相对拓扑
短句来源
     The twopreparations of erythromycin are of bioequivalence.
     结论:两种红霉素制剂具有生物等效性。
短句来源
查询“relative bioequivalence”译词为用户自定义的双语例句

    我想查看译文中含有:的双语例句
例句
没有找到相关例句


OBJECTIVE:To study the relative bioequivalence between ambroxol capsules(test drug)and its standard tablets(reference drug)and pharmacokinetics in 12 healthy male volunteers.METHODS:A dose of 90 mg of domestic of imported ambroxol(test and reference preparation)was given according to a randonized 2 way cross over disign, blood samples were withdrawn up to 24 hours post administation,and plasma concentration of ambroxol was determined by high performance liquid chromatography(HPLC).RESULTS:The concentration...

OBJECTIVE:To study the relative bioequivalence between ambroxol capsules(test drug)and its standard tablets(reference drug)and pharmacokinetics in 12 healthy male volunteers.METHODS:A dose of 90 mg of domestic of imported ambroxol(test and reference preparation)was given according to a randonized 2 way cross over disign, blood samples were withdrawn up to 24 hours post administation,and plasma concentration of ambroxol was determined by high performance liquid chromatography(HPLC).RESULTS:The concentration time curves of two preparations fitted to a one compartment model.The peak plasma levels( C max )of ambroxol test drug and reference drug were(385.5±98.3)and(378.9±90.3) μg·L -1 respectively,the peak time( T max )were(1.5±0.3) h and (1.6±0.4) h, AUC 0 t were(2421.2±761.3)and (2485.9±803.9) μg·h·L -1 ,respectively. The relative bioavailability of the test drug was(97.9±6.7)%.CONCLUSIONS:The pharmacokinetics and relative bioavailability data obtained in the study furnished definite proof of bioequivalence of both domestic ambroxol capsules and imported ambroxol tablets. [

目的 :研究被试制剂国产盐酸氨溴索胶囊和标准参比制剂 (沐舒坦R○)的药动学和人体生物等效性。方法 :采用高效液相色谱法测定 12名健康受试者单剂量口服被试制剂或参比制剂 90mg后 ,血浆中盐酸氨溴索的浓度 ,经 3p97计算程序拟合 ,计算其药动学参数 ,比较其与标准参比制剂的人体生物等效性。结果 :经 3p97计算程序拟合 ,两者在体内的过程皆符合血管外给药一室模型 ,采用梯形法计算的两者AUC0 -t均值分别为 (2 42 1.2± 76 1.3) μg·h·L-1和 (2 485 .9± 80 3 .9) μg·h·L-1,实测Cmax均值分别为 (385 .5± 98.3) μg·L-1和 (378.9± 90 .3) μg·L-1,实测Tpeak均值分别为 (1.5± 0 .3)h和 (1.6± 0 .4)h。被试制剂的相对生物利用度为 (97.9± 6 .7) %。结论 :经统计学分析 ,被试制剂和标准参比制剂具有生物等效性

Objective: To study the bioequivalence of ranitidine in 10 normal male volunteers. Methods: A single oral dose of 150 mg ranitidine hydrochloride effervescent granules or capsules of ranitidine was given according to across over design. The concentration in plasma was determined by HPLC. The extract was analyzed subsequently on ALLTIMA C18 column with 0.02 mol·L-1 potassium dihydrogen phosphate - methanol ( 70:30) as mobile phase, the flow rate was 1.0 mL·min-1, detected at 320 mn. Results: The concentration...

Objective: To study the bioequivalence of ranitidine in 10 normal male volunteers. Methods: A single oral dose of 150 mg ranitidine hydrochloride effervescent granules or capsules of ranitidine was given according to across over design. The concentration in plasma was determined by HPLC. The extract was analyzed subsequently on ALLTIMA C18 column with 0.02 mol·L-1 potassium dihydrogen phosphate - methanol ( 70:30) as mobile phase, the flow rate was 1.0 mL·min-1, detected at 320 mn. Results: The concentration - time curves of ranitidine hydrochloride effervescent granules and capsules products fitted to two - compartment open model. The main pharmacokinetic parameters were: Tpeak (1.96±0.55) h and (2.21±0.39) h, Cmax (665±213)μg·L-1 and (547±181)μg·L-1,AUC (3452± 601) h·μg·L-1 and (3 053±579) h·μg·L-1 . The pharmacokinetic parameters obtained from our studies showed no significant difference between the two products ( P > 0.05) . By content calibration relative bioequivalence of ranitidine hydrochloride effervescent granules was 108% . Conclusion: The results suggested that the bioequivalence of the twe preparations was similar.

目的:测定盐酸雷尼替丁泡腾颗粒剂的生物等效性。方法:10名男性健康志愿者交叉口服盐酸雷尼替丁泡腾颗粒剂和盐酸雷尼替丁胶囊,采用HPLC法测定人血清中药物浓度进行生物等效性的研究。以ALLTMA C18为固定相,0.02mol·L-1磷酸二氢钾溶液-甲醇(70:30)为流动相,流速1.0mL·min-1,检测波长为320nm。结果:泡腾颗粒剂与胶囊的血药浓度曲线均符合二室模型。其主要药物动力学参数:Tpeak分别为(1.96±0.55)h和(2.21±0.39)h,Cmax分别为(665±213)μg·L-1和(547±181)μg·L-1,AUC分别为(3452±601)h·μg·L-1和(3053±579)h·μg·L-1。各参数经配对t-检验处理,均无显著差异(P>0.05),泡腾颗粒剂的生物等效性经含量校正后为108%。结论:结果表明泡腾颗粒剂与胶囊剂具有生物利用等效性。

Objective:To study the relative bioequivalence of domestic and imported amoxicillin and clavulanic acid tablets.Methods:The randomized and crossover study was conducted in 10 healthy male volunteers.After a single dose of the drugs their plasma drug concentration was determined by microbiological assay.Results:Both the domestic and imported tablets of amoxicillin and clavulanic acid fitted to one compartment model.The pharmacokinetics parameters obtained were:C max =(5.17± 0.45 )mg/L,T max =(1.05±0.16)h,t...

Objective:To study the relative bioequivalence of domestic and imported amoxicillin and clavulanic acid tablets.Methods:The randomized and crossover study was conducted in 10 healthy male volunteers.After a single dose of the drugs their plasma drug concentration was determined by microbiological assay.Results:Both the domestic and imported tablets of amoxicillin and clavulanic acid fitted to one compartment model.The pharmacokinetics parameters obtained were:C max =(5.17± 0.45 )mg/L,T max =(1.05±0.16)h,t 1/2 =(1.16±0.17)h,AUC 0~t =(12.89±1.03)(mg·h)/L for domestic amoxicillin;C max =(5.25±0.46)mg/L,T max =(1.08±0.23)h,t 1/2 =(1.37±0.23)h,AUC 0~t =(13.54±0.59)(mg·h)/L for imported amoxicillin;C max =(3.94±0.52)mg/L,T max = (1.10± 0.21)h,t 1/2 =(0.98±0.11)h,AUC 0~t =(8.25±0.92)(mg·h)/L for domestic clavulanic acid;C max =(4.10±0.35)mg/L,T max =(1.03±0.10)h,t 1/2 =(1.01±0.14)h,AUC 0~t =(8.18± 0.51) (mg·h)/L for imported clavulanic acid.The relative bioequivalence was:(95.3±7.3)% for amoxicillin;(100.6±6.0)% for clavulanic acid.Conclusion:The domestic and imported amoxicillin and clavulanic acid tablets are bioequivalence.

目的 :以进口阿莫西林 /克拉维酸片为对照 ,考察国产制剂的人体生物等效性。方法 :10名健康受试者随机交叉单剂量口服 2种制剂 (阿莫西林 2 5 0mg ,克拉维酸钾 12 5mg)后 ,采用微生物法测定血浆中药物浓度。结果 :血药浓度数据经 3P97拟合 ,两者的体内过程皆符合血管外口服给药一室模型 ,采用梯形法计算的阿莫西林AUC0~t分别为 (12 .89± 1.0 3)和 (13.5 4± 0 .5 9) (mg·h) /L ,实测Cmax分别为 (5 .17± 0 .45 )和 (5 .2 5± 0 .46 )mg/L ;Tmax分别为 (1.0 5± 0 .16 )和 (1.0 8± 0 .2 3)h ,t1/ 2 分别为 (1.16± 0 .17)和 (1.37± 0 .2 3)h。克拉维酸钾的AUC0~t分别为 (8.2 5± 0 .92 )和 (8.18± 0 .5 1) (mg·h) /L ,实测Cmax分别为 (3 .94± 0 .5 2 )和 (4 .10± 0 .35 )mg/L ;Tmax分别为(1.10± 0 .2 1)和 (1.0 3± 0 .10 )h ,t1/ 2 分别...

目的 :以进口阿莫西林 /克拉维酸片为对照 ,考察国产制剂的人体生物等效性。方法 :10名健康受试者随机交叉单剂量口服 2种制剂 (阿莫西林 2 5 0mg ,克拉维酸钾 12 5mg)后 ,采用微生物法测定血浆中药物浓度。结果 :血药浓度数据经 3P97拟合 ,两者的体内过程皆符合血管外口服给药一室模型 ,采用梯形法计算的阿莫西林AUC0~t分别为 (12 .89± 1.0 3)和 (13.5 4± 0 .5 9) (mg·h) /L ,实测Cmax分别为 (5 .17± 0 .45 )和 (5 .2 5± 0 .46 )mg/L ;Tmax分别为 (1.0 5± 0 .16 )和 (1.0 8± 0 .2 3)h ,t1/ 2 分别为 (1.16± 0 .17)和 (1.37± 0 .2 3)h。克拉维酸钾的AUC0~t分别为 (8.2 5± 0 .92 )和 (8.18± 0 .5 1) (mg·h) /L ,实测Cmax分别为 (3 .94± 0 .5 2 )和 (4 .10± 0 .35 )mg/L ;Tmax分别为(1.10± 0 .2 1)和 (1.0 3± 0 .10 )h ,t1/ 2 分别为 (0 .98± 0 .11)和 (1.0 1± 0 .14)h。阿莫西林的相对生物利用度为 (95 .3±7.3) % ;克拉维酸钾的相对生物利用度为 (10 0 .6± 6 .0 ) %。结论 :经统计学分析 ,被试制剂和参比制剂具有生物等效性

 
<< 更多相关文摘    
图标索引 相关查询

 


 
CNKI小工具
在英文学术搜索中查有关relative bioequivalence的内容
在知识搜索中查有关relative bioequivalence的内容
在数字搜索中查有关relative bioequivalence的内容
在概念知识元中查有关relative bioequivalence的内容
在学术趋势中查有关relative bioequivalence的内容
 
 

CNKI主页设CNKI翻译助手为主页 | 收藏CNKI翻译助手 | 广告服务 | 英文学术搜索
版权图标  2008 CNKI-中国知网
京ICP证040431号 互联网出版许可证 新出网证(京)字008号
北京市公安局海淀分局 备案号:110 1081725
版权图标 2008中国知网(cnki) 中国学术期刊(光盘版)电子杂志社